Last updated: March 20, 2026
Case Overview
Dow Pharmaceutical Sciences, Inc. filed a patent infringement lawsuit against Taro Pharmaceuticals U.S.A., Inc. on February 28, 2017. The case involved allegations that Taro infringed upon Dow’s patent related to topical pharmaceutical compositions. The litigation covered patent validity, infringement scope, and potential damages.
Timeline and Key Proceedings
- Complaint Filing: Filed in the District of New Jersey on February 28, 2017.
- Patent Dispute: Concerned U.S. Patent No. 9,137,243, titled “Topical Pharmaceutical Compositions.”
- Preliminary Motions: Taro moved to dismiss or challenge patent validity.
- Claim Construction: Judge A. Talwani issued claim construction rulings.
- Summary Judgment Motions: Both parties filed motions regarding infringement and validity.
- Trial Date: Scheduled for late 2018 but was delayed multiple times.
- Settlements and Dispositions: The case was settled in 2020 before a final ruling.
Legal Issues
- Patent Validity: Taro challenged the patent’s validity based on prior art, obviousness, and written description.
- Infringement: Whether Taro’s generic formulations infringed proprietary claims.
- Damages: Whether Dow was entitled to monetary damages and injunctive relief based on infringement findings.
Technical and Legal Arguments
Taro’s Defenses
- Non-infringement: Argued Taro’s products did not meet the patent claims’ scope.
- Invalidity Arguments: Claimed the patent was obvious in light of prior art references such as PubMed articles and earlier patents, including U.S. Patent No. 8,273,649.
- Lack of Written Description: Alleged the patent lacked adequate disclosure to support claims.
Dow’s Position
- Claim Construction: Asserted the claims should be interpreted broadly to cover Taro’s formulations.
- Patent’s Novelty and Non-obviousness: Argued the patent represented a non-obvious improvement over prior art.
- Infringement: Maintained Taro’s products infringed key claims due to comparable formulation and therapeutic effect.
Court Decisions
- Claim Construction: The court adopted Dow’s proposed constructions for several key claims, favoring a broad interpretation.
- Summary Judgment: The court denied Taro’s motion to dismiss, allowing infringement and validity issues to proceed.
- Infringement Findings: Ultimately, the case was settled before the trial reached a definitive infringement ruling.
- Settlement: Both parties agreed to settle in 2020, avoiding a court ruling on patent validity and infringement.
Settlement and Resolution
The parties settled with undisclosed terms in 2020, ending all litigation. The settlement included a cross-licensing agreement and financial terms unspecified in public filings.
Patent and Market Impact
- The patent in question covers a class of topical compositions with specific emollient and therapeutic properties.
- Its validity remains challenged but unlitigated post-settlement.
- The case exemplifies legal defenses available to generics facing patent assertions, including claims of obviousness and insufficient disclosure.
Strategic Implications
- Companies filing patents in pharmaceutical formulations should ensure comprehensive documentation and robust claims.
- Generics companies should evaluate prior art thoroughly when challenging patents.
- Litigation can often be resolved through settlement, especially if patent validity is uncertain or damages are contested.
Key Takeaways
- The case underscores the importance of clear patent claims and detailed disclosures in pharmaceutical patents.
- Patent validity challenges often hinge on prior art and obviousness arguments.
- Settlement remains a common resolution in patent disputes to avoid costly litigation.
- The case exemplifies how courts interpret claim scope and validity arguments in pharmaceutical patent litigation.
Frequently Asked Questions
Q1: Did Taro infringe Dow’s patent?
A1: The case was settled before a final infringement ruling was made.
Q2: What were the main validity challenges raised by Taro?
A2: Taro challenged patent validity based on prior art, obviousness, and lack of written description.
Q3: How did the court interpret the patent claims?
A3: The court adopted broad interpretations, favoring Dow’s construction.
Q4: Was there a court decision on patent infringement?
A4: No, the case settled before a final infringement ruling.
Q5: What lessons can pharmaceutical patent filers learn from this case?
A5: Ensure claims are supported by comprehensive disclosures and anticipate validity challenges.
References
[1] U.S. District Court for the District of New Jersey. (2017). Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc., No. 2:17-cv-00544.
[2] Patent No. 9,137,243. (2015). “Topical Pharmaceutical Compositions.” U.S. Patent and Trademark Office.
[3] Court docket entries and settlement documents filed in the case, 2020.
[4] appellate and legal analysis based on publicly available case summaries and patent law principles.
